Zobrazeno 1 - 10
of 599
pro vyhledávání: '"W. Mellors"'
Autor:
Xiaojie Chu, Seungmin Shin, Du-San Baek, Liyong Zhang, Alex Conard, Megan Shi, Ye-Jin Kim, Cynthia Adams, Maggie Hines, Xianglei Liu, Chuan Chen, Zehua Sun, Dontcho V. Jelev, John W. Mellors, Dimiter S. Dimitrov, Wei Li
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Prostate stem cell antigen (PSCA) is expressed in all stages of prostate cancer, including in advanced androgen-independent tumors and bone metastasis. PSCA may associate with prostate carcinogenesis and lineage plasticity in prostate cancer. PSCA is
Externí odkaz:
https://doaj.org/article/1f085d6811ce4dcda8bde14f50a5302f
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-14 (2024)
Abstract High-grade serous ovarian carcinoma (HGSOC) is a heterogeneous disease, and a highstromal/desmoplastic tumor microenvironment (TME) is associated with a poor outcome. Stromal cell subtypes, including fibroblasts, myofibroblasts, and cancer-a
Externí odkaz:
https://doaj.org/article/d5d7b14c4f4748f69d01ef7ad1aa76cf
Autor:
Alison Morris, Barbara Methe, Xiaohong Wang, Georgios D Kitsios, Frank C Sciurba, Eva Szigethy, Lili Jiang, Shawna Blacka, Jana J Jacobs, Taaha Mirza, Asma Naqvi, Heather Gentry, Cathy Murray, Konstantin Golubykh, Hafiz Qurashi, Akash Dodia, Michael Risbano, Michael Benigno, Birol Emir, Edward Weinstein, Candace Bramson, Feng Dai, John W Mellors, Seyed Mehdi Nouraie
Publikováno v:
BMJ Open, Vol 14, Iss 3 (2024)
Objective To characterise subphenotypes of self-reported symptoms and outcomes (SRSOs) in postacute sequelae of COVID-19 (PASC).Design Prospective, observational cohort study of subjects with PASC.Setting Academic tertiary centre from five clinical r
Externí odkaz:
https://doaj.org/article/1768a7cb44344d278d9a06c6124e6b66
Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents
Autor:
Zehua Sun, Ambika P. Jaswal, Xiaojie Chu, Harikrishnan Rajkumar, Angel G. Cortez, Robert Edinger, Max Rose, Anders Josefsson, Abhinav Bhise, Ziyu Huang, Rieko Ishima, John W Mellors, Dimiter S. Dimitrov, Wei Li, Jessie R. Nedrow
Publikováno v:
ACS Omega, Vol 8, Iss 46, Pp 43586-43595 (2023)
Externí odkaz:
https://doaj.org/article/60e4da078bb04806b5cc89b96027a3cd
Autor:
Zehua Sun, Xiaojie Chu, Cynthia Adams, Tatiana V. Ilina, Michel Guerrero, Guowu Lin, Chuan Chen, Dontcho Jelev, Rieko Ishima, Wei Li, John W. Mellors, Guillermo Calero, Dimiter S. Dimitrov
Publikováno v:
Molecular Therapy: Oncolytics, Vol 31, Iss , Pp 100726- (2023)
Mesothelin (MSLN) has been a validated tumor-associated antigen target for several solid tumors for over a decade, making it an attractive option for therapeutic interventions. Novel antibodies with high affinity and better therapeutic properties are
Externí odkaz:
https://doaj.org/article/e3ac5eca01cc47a6b9a22161f0b5c4b7
Autor:
Chuan Chen, Zehua Sun, Zening Wang, Seungmin Shin, Abigail Berrios, John W. Mellors, Dimiter S. Dimitrov, Wei Li
Publikováno v:
Antibodies, Vol 13, Iss 2, p 39 (2024)
The anaplastic lymphoma kinase (ALK, CD247) is a potential target for antibody-based therapy. However, no antibody-based therapeutics targeting ALK have entered clinical trials, necessitating the development of novel antibodies with unique therapeuti
Externí odkaz:
https://doaj.org/article/1841d17e6802452dac45208d88414a5b
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The high expression of uPAR has been linked to tumor progression, invasion, and metastasis in several types of cancer. Such overexpression of uPAR makes it a potential target for immunotherapies across common cancers such as breast, colorectal, lung,
Externí odkaz:
https://doaj.org/article/125c75797b304e3b90966c066708f5ad
Autor:
Dennis C. Copertino Jr., Carissa S. Holmberg, Jared Weiler, Adam R. Ward, J. Natalie Howard, Callie Levinger, Alina P.S. Pang, Michael J. Corley, Friederike Dündar, Paul Zumbo, Doron Betel, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Noemi Linden, Bernard J. Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, Colin Kovacs, Erika Benko, Alberto Bosque, R. Brad Jones, for the AIDS Clinical Trials Group (ACTG) A5321 Team
Publikováno v:
JCI Insight, Vol 8, Iss 18 (2023)
IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydr
Externí odkaz:
https://doaj.org/article/ed18029fbf2043e591567763be3f9138
Autor:
Robert A. Salata, Beatriz Grinsztejn, Justin Ritz, Ann C. Collier, Evelyn Hogg, Robert Gross, Catherine Godfrey, Nagalingeswaran Kumarasamy, Cecilia Kanyama, John W. Mellors, Carole L. Wallis, Michael D. Hughes, the ACTG A5288 Study Team
Publikováno v:
AIDS Research and Therapy, Vol 20, Iss 1, Pp 1-11 (2023)
Abstract Background Treatment management after repeated failure of antiretroviral therapy (ART) is difficult due to resistance and adherence challenges. For people who have failed non-nucleoside reverse transcriptase inhibitor-(NNRTI-) and protease i
Externí odkaz:
https://doaj.org/article/5944af9cb8954da08f8eab2461c49ae1
Autor:
Johannes C. Botha, Dimiter Demirov, Carli Gordijn, Mary Grace Katusiime, Michael J. Bale, Xiaolin Wu, Daria Wells, Stephen H. Hughes, Mark F. Cotton, John W. Mellors, Mary F. Kearney, Gert U. van Zyl
Publikováno v:
mBio, Vol 14, Iss 4 (2023)
ABSTRACT Combination antiretroviral therapy (cART) suppresses viral replication but does not cure HIV infection because a reservoir of infectious (intact) HIV proviruses persists in long-lived CD4+T cells. However, a large majority (>95%) of HIV-infe
Externí odkaz:
https://doaj.org/article/d5d9f7ebe1244d2c9af51df313d4cec7